Barinthus Biotherapeutics Q1 EPS $(0.40) Beats $(0.54) Estimate
Portfolio Pulse from Benzinga Newsdesk
Barinthus Biotherapeutics (NASDAQ:BRNS) reported Q1 EPS of $(0.40), beating the $(0.54) estimate, marking a 25.93% beat and a 16.67% improvement over last year's $(0.48) per share loss.
May 13, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barinthus Biotherapeutics reported a smaller than expected Q1 loss per share, beating estimates and showing improvement over the previous year.
Beating EPS estimates typically leads to positive investor sentiment, potentially driving up the stock price in the short term. The improvement over the previous year's loss further strengthens the case for a positive impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100